Formation à l'injection intra-articulaire de cellules souches chez le chien arthrosique
Read more
Précédent
Suivant
Vetbiobank develops neonatal stem cell-based cellular drugs with unique potential to fight dogs, cats and horses' chronic inflammatory diseases. Whether they are sick, injured or just old, they help restore their quality of life and well-being.
You are a French speaking practioner? Discover the latest information on our products in development
Already registered
Come and meet Vetbiobank's management team
Formation à l'injection intra-articulaire de cellules souches chez le chien arthrosique
Read moreThe Vetbiobank team would like to wish a very happy birthday to "Chaussette" who was one of our first patients who, as part of a clinical trial, received stem cells in 2014 to manage his osteoarthritis of the elbow.Â
Read morefor its pharmaceutical manufacturing activities.
Read moreOur "SmartCellFactory" project is the winner of the "Re)localization" call for projects of the France Recovery Plan.
Read moreVetbiobank deploys its intellectual property protection strategy internationally and expands its patent portfolio with: A regional phase covering high-potential geographical areas and an additional international PCT filing.Â
Read moreOur new website is online, we invite you to surf on our internet site and discover Vetbiobank's expertise in cell therapy for animal health.
Read morePionnier de la me?decine re?ge?ne?rative ve?te?rinaire, la jeune pousse en voie de diversification est en phase de leve?e de fonds pour financer ses e?tudes cliniques et?
Read more
6th bioproduction congress
30 Sept.-1 Oct. 2021, Lyon, France
« Bioproduction Challenges & Opportunities for Biotherapies ; lessons learned form COVID-19 pandemic »
This event will bring together experts from companies (big pharmas, SME and Startups) and laboratories developing therapeutic candidates as well as leading bioproduction professionals to accelerate therapeutics drugs such as mAbs, vaccines, cell therapy and novel products into commercial manufacturing.
To develop cellular therapies for veterinary use, to improve and lighten the management of chronic inflammatory animal diseases.
Then to produce them industrially in order to make them accessible to as many people as possible.
Grâce à leur potentiel biologique intact lié à leur jeunesse, les cellules souches néonatales, peuvent agir sur les causes responsables de nombreuses maladies inflammatoires chroniques qui affectent les articulations, l?appareil digestif, la peau, les muqueuses, ? des animaux
Vetbiobank develops its therapeutic innovations in order to bring:
– to animals, treatments that allow
– to pet owners, a solution
– to veterinarians, a comlementary expertise
Company
Technologies
Products
Partners
News
© 2021 Vetbiobank All Rights Reserved
Ask your veterinarian for the price of a stem cell injection at his clinic.
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
CANIPREN
|
VBX-01 |
|
|
|
|
|
|
|
|
CA0102 |
|
|
|
|
|
|
|
|
|
CA0103 |
|
|
|
|
|
|
|
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
FELIPREN
|
FE0101 |
|
|
|
|
|
|
|
|
FE0102 Chronic kidney failure |
|
|
|
|
|
|
|
|
|
FE0103 |
|
|
|
|
|
|
|
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
EQUIPREN
|
EQ0101 |
|
|
|
|
|
|
|
